Abstract
Clinicobacteriological effect of cefepime (in combination with amikacin) was studies in 25 pediatric patients of the age of 7 to 17 years with a mixed form of mucoviscidosis at the stage of the bronchopulmonary infection exacerbation. The basic pathogens isolated from the sputum were: Pseudomonas aeruginosa sm., P. aeruginosa muc. (67.5%) and Staphylococcus aureus (29.1%). The 2-week treatment course resulted in a marked clinical effect with improvement of the lung functional indices and eradication of the majority of the S. aureus strains (81.2%) and half of the P. aeruginosa strains (49.6%). The only side effect was moderate diarrhea not requiring discontinuation of the drug use.
MeSH terms
-
Adolescent
-
Anti-Bacterial Agents / adverse effects
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use*
-
Bronchial Diseases / complications
-
Bronchial Diseases / drug therapy*
-
Bronchial Diseases / microbiology
-
Cefepime
-
Cephalosporins / adverse effects
-
Cephalosporins / pharmacology
-
Cephalosporins / therapeutic use*
-
Child
-
Cystic Fibrosis / complications*
-
Female
-
Humans
-
Lung Diseases / complications
-
Lung Diseases / drug therapy*
-
Lung Diseases / microbiology
-
Male
-
Pseudomonas Infections / complications
-
Pseudomonas Infections / drug therapy
-
Pseudomonas aeruginosa / drug effects*
-
Pseudomonas aeruginosa / isolation & purification
-
Sputum / microbiology
-
Staphylococcal Infections / complications
-
Staphylococcal Infections / drug therapy
-
Staphylococcus aureus / drug effects*
-
Staphylococcus aureus / isolation & purification
Substances
-
Anti-Bacterial Agents
-
Cephalosporins
-
Cefepime